Glycated Haemoglobin (HbA1c) Testing Market

News provided by

Research and Markets

23 Sep, 2014, 17:38 GMT

DUBLIN, Sept. 23, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Glycated Haemoglobin (HbA1c) Testing Market" report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

Continue Reading
This image opens in the lightbox
Research and Markets Logo. (PRNewsFoto/PR NEWSWIRE EUROPE)

Diabetes is a chronic disease growing at an alarming rate across the globe. Over 382 million people are estimated to be currently suffering from the disease; the number is likely to increase to 592 million by 2035.

With a very high prevalence, especially in some regions such as China and India, an increasing proportion of diabetic patients are likely to benefit from more efficient and accurate diagnostic tests in the future. Furthermore, an efficient measurement of the condition can help lower the rate of serious complications, such as heart attack and stroke. HbA1c, adapted for clinical testing to monitor diabetes in 1990s, is one such test; it can monitor and give average glucose results over the past 120 days. The test offers significant advantages over usual blood glucose monitoring assays; these include no prior fasting requirement, high sample stability, low day-to-day variation and limited impact from external physical factors such as stress.

The adoption of HbA1c tests has gradually risen in the recent past. While the laboratory analyzers are likely to strengthen their existing position, a significant growth will also be driven by Point of Care (POC) devices. POC devices bring a change in overall diabetes management and the lifestyle of the individual. Compared to laboratory tests, they can be used at home or physician's office with instantaneous results and accuracy. In addition, considering the lifetime costs, POC testing is comparatively cheaper than laboratory testing. Increased efforts to overcome lack of awareness, especially in emerging markets, are also expected to drive adoption levels further.

With a large number of devices already in market for HbA1c testing and more to come in the future years, HbA1c market is likely to shape up much better in the coming years. We have strong reasons to believe that the overall market outlook will stay positive in the mid-long term.

The Glycated Haemoglobin (HbA1c) Testing Market, 2014-2024 report provides an exhaustive study of the growing market for HbA1c tests. Amongst other things, the report identifies HbA1c analyzers that are currently available for point of care and laboratory testing, and the high level trends which are likely to govern the evolution of this market in the US, EU5 and BRICS countries. The report also provides a competitive landscape wherein we have identified the most efficient POC devices in the market based on parameters such as user friendliness and other technical details.

Companies Mentioned:

  • A Menarini
  • AC Immune SA
  • AT&T
  • Aalto Scientific
  • AbD Serotec
  • Abbott
  • Afinion
  • Agappe
  • Alere
  • Alfa Wassermann
  • Apex Bio
  • ArkRay
  • Ascletis
  • Axis Shield
  • Beckman Coulter
  • Beijing Automotive Industry Holding
  • Beijing Shining Sun
  • Bio-Rad
  • Biohermes
  • Boditech
  • CFR Pharmaceuticals
  • Carolina Liquid
  • Ceragem
  • Chek Diagnostics
  • Chiasma Inc.
  • Ci-Co Healthcare
  • Constitution Medical Inc.
  • Convergent Technologies
  • Diasys Diazyme
  • Diazyme Laboratories
  • Discuvia Ltd.
  • Drew Scientific
  • EKF Diagnostics
  • ELITech
  • Epocal
  • Eurolyser
  • FIOMI Diagnostics
  • Freescale Semiconductors
  • Hitachi
  • Hitado
  • Horiba Medical
  • Human Diagnostics
  • IDEV Technologies
  • Immatics Biotechnologies
  • Immco Diagnostics
  • Inception Sciences Inc.
  • Infopia
  • Inovio
  • Isis Pharma
  • JANSSEN & Pharmacyclics
  • Jeol
  • KUKA
  • Kyowa Medex
  • LAB 21
  • Mec Dynamics
  • Merisant
  • Mitsubishi
  • Molecular Partners
  • MorphoSys AG
  • Myriad RBM, Inc.
  • Nihon Kohden
  • OptiMedica
  • Ortho Clinical Diagnostics
  • Oryzon Genomics
  • Piramal Healthcare
  • Pointe Scientific
  • Polyphor Ltd.
  • Prothena Corporation
  • Quest Diagnostics
  • Radiometer
  • Randox laboratories
  • Relay Technology Management
  • Roche
  • Rohm
  • SD Biosensor
  • Sakae Corporation
  • Samsung
  • Sanwa Kagaku Kenkyusho Co. ltd
  • Sebia
  • Sekisui Medical
  • Shenzhen Lifotronic
  • Siemens Healthcare
  • Streck, Inc.
  • Toshiba
  • Tosoh Biosciences
  • Trinity Biotech
  • Tulip Reagents
  • Valeant Pharmaceuticals
  • Veropharm
  • Versant Ventures
  • Wako Pure Chemical industries
  • Wiener laboratories

For more information visit http://www.researchandmarkets.com/research/tx3kdg/glycated

Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net